A novel anti‑EGFR monoclonal antibody (EMab‑17) exerts antitumor activity against oral squamous cell carcinomas via antibody‑dependent cellular cytotoxicity and complement‑dependent cytotoxicity
Journal article published in 2020 by
Junko Takei,
Mika Kaneko,
Tomokazu Ohishi,
Manabu Kawada,
Hiroyuki Harada,
Yukinari Kato 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Postprint:
archiving forbidden
Data provided by 